TITLE:
Preliminary Findings on the Use of Targeted Therapy with Pazopanib and Other Agents in Combination with Sodium Phenylbutyrate in the Treatment of Glioblastoma Multiforme
AUTHORS:
Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Sheldon Brookman
KEYWORDS:
Gliobastoma Multiforme, Personalized Targeted Agents, Sodium Phenylbutyrate, Treatment of Glioblastoma Multiforme
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.14,
December
25,
2014
ABSTRACT: The most common and aggressive type of brain
tumor is glioblastoma multiforme (GBM). The prognosis for GBM remains poor with
a five-year survival rate between 1% and 2%. The prospects for patients with
recurrent GBM (RGBM) are much worse, with the majority dying within 6 months.
This publication provides a brief description of the treatment of 11 GBM patients
treated with sodium phenylbutyrate (PB) in combination with pazopanib, m-TOR
inhibitors, and other agents. The treatment was associated with tolerable side
effects and resulted in objective responses in 54.5% of cases (complete
response 18.2%, partial response 36.3%) and 27.3% cases of stable disease. The
preferable treatment regimen consisted of PB, pazopanib, dasatinib, everolimus,
and bevacizumab (BVZ). For various reasons not all patients were compliant with
the treatment regimen. In patients who strictly complied with the treatment
plan, all responded as CR or PR. Based on preliminary findings, the authors
propose further phase I/II clinical trials with PB in combination with
pazopanib, dasatinib, everolimus, and BVZ in patients with RGBM who failed
standard surgery, radiation therapy and chemotherapy. With proper dose
reductions, the treatment appears to be well-tolerated. Molecular profiling of patient
subgroups with favorable genomic signatures may help to select patients for
future studies.